<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN" "JATS-archivearticle1-3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">JPSIM</journal-id>
      <journal-title-group>
        <journal-title>Journal of Pakistan Society of Internal Medicine</journal-title>
        <abbrev-title>J Pak Soc Intern Med</abbrev-title>
      </journal-title-group>
      <issn publication-format="print">2709-8729</issn>
      <issn publication-format="electronic">2710-0804</issn>
      <publisher>
        <publisher-name>Pakistan Society of Internal Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.70302/jpsim.v5i3.2455</article-id>
      <article-id pub-id-type="publisher-id">jpsim.v5i3.2455</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pediatric Acute Lymphoblastic Leukemia in Rawalpindi</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Ikramullah</surname>
            <given-names>Ikramullah</given-names>
          </name>
          <email>khanikramullah038@gmail.com</email>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Saleem</surname>
            <given-names>Shafaq</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Saad</surname>
            <given-names>Ammar Bin</given-names>
          </name>
          <xref ref-type="aff" rid="aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rehman</surname>
            <given-names>Naumana</given-names>
          </name>
          <xref ref-type="aff" rid="aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mufti</surname>
            <given-names>Maleeha Zia</given-names>
          </name>
          <xref ref-type="aff" rid="aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Malik</surname>
            <given-names>Saira Nasr</given-names>
          </name>
          <xref ref-type="aff" rid="aff4"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <institution>Combined Military Hospital, Abbottabad,</institution>
      </aff>
      <aff id="aff2">
        <institution>Gomal Medical College, Dera Ismail Khan</institution>
      </aff>
      <aff id="aff3">
        <institution>Ayub Medical College, Abbottabad</institution>
      </aff>
      <aff id="aff4">
        <institution>Khyber Medical College, Peshawar.</institution>
      </aff>
      <author-notes>
        <corresp id="cor1">*Correspondence: Ikramullah Ikramullah (khanikramullah038@gmail.com)</corresp>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic" iso-8601-date="2024-08-30">
        <day>30</day>
        <month>08</month>
        <year>2024</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2024</year>
      </pub-date>
      <volume>5</volume>
      <issue>3</issue>
      <fpage>635</fpage>
      <lpage>639</lpage>
      <history>
        <date date-type="received" iso-8601-date="2024-02-16">
          <day>16</day>
          <month>02</month>
          <year>2024</year>
        </date>
        <date date-type="accepted" iso-8601-date="2024-08-06">
          <day>06</day>
          <month>08</month>
          <year>2024</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright © 2024 The Author(s)</copyright-statement>
        <copyright-year>2024</copyright-year>
        <copyright-holder>The Author(s)</copyright-holder>
        <ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="https://psimj.com/article/jpsim.v5i3.2455" content-type="text/html"/>
      <self-uri xlink:href="https://psimj.com/article/jpsim.v5i3.2455.pdf" content-type="application/pdf"/>
      <abstract>
        <sec>
          <title>Objective</title>
          <p>To identify the incidences of ALL, it’s Diagnostic, clinical and its prognostic aspect from CMH Rawalpindi hospital Pakistan</p>
        </sec>
        <sec>
          <title>Methodology</title>
          <p>Diagnosis and screening for ALL was done at CMH Rawalpindi from 2010-2021. During this time, 981 individuals under the age of 19 who had recently been diagnosed with acute lymphoblastic leukemia. Cytological, immunophenotypic, and cytogenetic criteria were employed to diagnose. Chi-square and Fisher's exact tests assessed prognostic factor associations.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>The collected data from 2010-2021, showed that Males predominated the incidence rate 626 (63.8%), average diagnostic age was 6.3-0.5 years. Results showed that 207(21.10%) were children less than 3 years old, 587(59.80%) were between 3-10 years old. While 187(19%) were above age of 10. After statistical analysis, patients at standard risk were found to be (496)50.5% while 485(49.5%) were at high risk. The collected data reported prevalence of ALL in (850)86.6% patients while 131(13.3%) patients were diagnosed with Albl. The survival rate of patients having disease and that of survival rate with disease free conditions was found in 655(66.7%) and 326(33.3%) patients respectively. Patients with normal nutritional status 726(74%), with moderate eating 165(16.80%) and eating severely 90(9.2%) was reported and analyzed.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>ALL is found to be one of threat in young children and adolescence. There is a threat of relapse even after recovery from ALL when treated specifically in adolescence. Early prognosis and diagnosis of ALL is necessary to mitigate its effects and to avoid its recurrence. Health authorities in this regard should provide the required facilities to overcome this menace.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en" kwd-group-type="author-keywords">
        <title>Keywords</title>
        <kwd>Acute Lymphoblastic Leukemia</kwd>
        <kwd>Malignancy</kwd>
        <kwd>T-ALL</kwd>
        <kwd>Standard risk</kwd>
        <kwd>High risk.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <!-- <body> omitted: no manuscript (.docx) on file -->
  <back>
    <ref-list>
      <title>References</title>
      <ref id="ref1">
        <label>1</label>
        <mixed-citation>Bhatia S, Robison LLJOoI, Childhood. Philadelphia PSE. Epidemiology of leukemia in childhood. 2009:3-25.</mixed-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <mixed-citation>Pui C-H, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2011;29(4):386.</mixed-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <mixed-citation>Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100(1):52-8.</mixed-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <mixed-citation>Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial all-bfm 95. Rand Control Trial. 2008;11(9): 4477-89.</mixed-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <mixed-citation>Friedmann AM, Weinstein HJJTo. The role of prognostic features in the treatment of childhood acute lymphoblastic leukemia. Oncologist. 2000;5(4):321-8.</mixed-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <mixed-citation>Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A children's oncology group study. Blood. 2008;111(12):5477-85.</mixed-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <mixed-citation>Arico M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, et al. Long-term results of the aieop-all-95 trial for childhood acute lymphoblastic leukemia: Insight on the prognostic value of DNA index in the framework of berlin-frankfurt-muenster–based chemotherapy. J Clin Oncol. 2008;26(2):283-9.</mixed-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <mixed-citation>Leite EP, Muniz MTC, Azevedo AdCACd, Souto FR, Maia ÂCL, Gondim CMdF, et al. Fatores prognósticos em crianças e adolescentes com leucemia linfóide aguda. Rev Bras Saude Mater Infant. 2007;7(4):413-21.</mixed-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <mixed-citation>Pereira WV. Aspectos epidemiológicos, biotipologia e evolução do tratamento da leucemia linfocítica aguda na infância e adolescência no rio grande do sul: Universidade de São Paulo; 2010.</mixed-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <mixed-citation>Schrappe M, Camitta B, Pui CJL. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000;14(12):2193-4.</mixed-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <mixed-citation>Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, et al. Childhood t-cell acute lymphoblastic leukemia: The dana-farber cancer institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21(19):3616-22.</mixed-citation>
      </ref>
      <ref id="ref12">
        <label>12</label>
        <mixed-citation>Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of dana-farber consortium protocol 91-01. Blood. 2001;97(5):1211-8.</mixed-citation>
      </ref>
      <ref id="ref13">
        <label>13</label>
        <mixed-citation>Dastugue N, Suciu S, Plat G, Speleman F, Cavé H, Girard S, et al. Hyperdiploidy with 58-66 chromosomes in childhood b-acute lymphoblastic leukemia is highly curable: 58951 clg-eortc results. Blood. 2013;121(13):2415-23.</mixed-citation>
      </ref>
      <ref id="ref14">
        <label>14</label>
        <mixed-citation>Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children's cancer group and cancer and leukemia group b studies. Blood. 2008;112(5):1646-54.</mixed-citation>
      </ref>
      <ref id="ref15">
        <label>15</label>
        <mixed-citation>Manabe A, Ohara A, Hasegawa D, Koh K, Saito T, Kiyokawa N, et al. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: The tokyo children’s cancer study group study l99-15. Hematologica. 2008;93(8):1155-60.</mixed-citation>
      </ref>
      <ref id="ref16">
        <label>16</label>
        <mixed-citation>Brandalise SR. Prognostic value of day 8 peripheral blood responce for children with acute lymphocytic leukemia. Gene technology: Stem cell and leukemia research: Springer; 1996. p. 421-8.</mixed-citation>
      </ref>
      <ref id="ref17">
        <label>17</label>
        <mixed-citation>Sousa DWLd, Ferreira FVdA, Félix FHC, Lopes MVdOJRbdheh. Acute lymphoblastic leukemia in children and adolescents: Prognostic factors and analysis of survival. Rev Brasil Hematol Hemoter. 2015;37(7):223-9.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
